ArticleTranslational cancer research2026
Clinicopathological characteristics and prognosis of pulmonary spindle cell carcinoma: a population-based retrospective study using SEER data.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary spindle cell carcinoma (PSCC) is a rare pulmonary sarcomatoid carcinoma subtype accounting for 0.17-0.4% of lung malignancies. Due to its rarity, its clinicopathological features and prognostic factors remain poorly characterized. This retrospective study evaluated the clinical characteristics and survival-associated factors of PSCC. Methods: Patients with PSCC and other non-small cell lung cancers (NSCLCs) diagnosed between 2004 and 2014 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. In response to disease-definition concerns, the primary reanalysis was restricted to International Classification of Diseases for Oncology, Third Edition (ICD-O-3) code 8032/3. Cancer-specific survival (CSS) and overall survival (OS) were analyzed using Kaplan-Meier and Cox proportional hazards regression models. Tumor-node-metastasis (TNM) stage and other clinicopathological variables were evaluated, and an internally derived CSS prognostic model was rebuilt. Results: The strict PSCC cohort included 250 ICD-O-3 8032/3 patients and was compared with 220,703 other NSCLC patients. Strict PSCC patients had a median age of 72 years, 53.6% were male, 28.4% had stage III disease, and 47.6% had stage IV disease. Compared with other NSCLCs, strict PSCCs were larger and less differentiated. Median CSS was 5 months, with 1-, 3-, 5-, and 10-year CSS rates of 29.2%, 17.6%, 16.3%, and 14.7%, respectively. Median OS was 4 months, with 1-, 3-, 5-, and 10-year OS rates of 27.1%, 14.8%, 13.2%, and 8.5%, respectively. In multivariable CSS analysis, female sex, lower T/N/M stages, surgery, and chemotherapy were associated with longer CSS. The rebuilt CSS model had a C-index of 0.757. Conclusions: Strictly defined PSCC exhibits aggressive clinicopathological features and poor CSS and OS. Treatment-related findings should be interpreted as associations rather than causal evidence of treatment benefit because treatment allocation was not randomized and key confounders were unavailable. The internally derived prognostic model may provide exploratory prognostic information but requires external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.